{"id":165161,"date":"2026-07-22T17:26:13","date_gmt":"2026-07-22T11:56:13","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=165161"},"modified":"2026-07-22T17:26:14","modified_gmt":"2026-07-22T11:56:14","slug":"dr-reddys-labs-q1-results-fy27-pat-444-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/","title":{"rendered":"Dr Reddy&#8217;s Labs Q1 Results FY27: Net Profit Plunges 68.7% to Rs 444 Crore, Misses Estimates Sharply"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Dr Reddy&#8217;s Q1 FY27: PAT Rs 444 Cr, down 68.7% YoY, vs estimate of Rs 737 Cr. Revenue Rs 8,100 Cr, down 5.5%. Margin falls to 10.6% from 25.3%. Stock down 1.92% at Rs 1,182.80.<\/em><\/p>\n<p>Dr Reddy&#8217;s Labs Q1 results FY27 were announced on Wednesday, 22 July 2026, with the pharmaceutical major&#8217;s Dr Reddy&#8217;s Labs Q1 results FY27 showing a consolidated net profit of Rs 444 crore for the quarter ended 30 June 2026, down 68.7% from Rs 1,418 crore in the year ago quarter and well short of the Street estimate of Rs 737 crore. Revenue declined 5.5% to Rs 8,100 crore, also missing the estimate of Rs 8,221 crore.<\/p>\n<p>Shares of <a href=\"https:\/\/univest.in\/stocks\/drreddy\/dr-reddy's-laboratories-ltd-share-price-today\">Dr Reddy&#8217;s Laboratories<\/a> fell 1.92% to Rs 1,182.80 on the NSE on the results day, as the market reacted to a sharp miss across every key metric.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=dr-reddys-q1-fy27-pat\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#Dr_Reddys_Labs_Q1_Results_FY27_Key_Takeaways\" title=\"Dr Reddy&#8217;s Labs Q1 Results FY27 Key Takeaways\">Dr Reddy&#8217;s Labs Q1 Results FY27 Key Takeaways<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#Dr_Reddys_Labs_Q1_Results_FY27_Financial_Highlights\" title=\"Dr Reddy&#8217;s Labs Q1 Results FY27 Financial Highlights\">Dr Reddy&#8217;s Labs Q1 Results FY27 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#Dr_Reddys_Labs_Q1_Results_FY27_Performance_Analysis\" title=\"Dr Reddy&#8217;s Labs Q1 Results FY27 Performance Analysis\">Dr Reddy&#8217;s Labs Q1 Results FY27 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#Dr_Reddys_Labs_Q1_Results_FY27_Key_Business_Factors\" title=\"Dr Reddy&#8217;s Labs Q1 Results FY27: Key Business Factors\">Dr Reddy&#8217;s Labs Q1 Results FY27: Key Business Factors<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#1_US_Generics_Pricing_and_Competitive_Pressure\" title=\"1. US Generics Pricing and Competitive Pressure\">1. US Generics Pricing and Competitive Pressure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#2_Semaglutide_Supply_Delay\" title=\"2. Semaglutide Supply Delay\">2. Semaglutide Supply Delay<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#3_Broad_Based_Miss_Against_Estimates\" title=\"3. Broad Based Miss Against Estimates\">3. Broad Based Miss Against Estimates<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#Dividend_Details\" title=\"Dividend Details\">Dividend Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#Dr_Reddys_Labs_Q1_Results_FY27_Outlook_for_the_Full_Year\" title=\"Dr Reddy&#8217;s Labs Q1 Results FY27 Outlook for the Full Year\">Dr Reddy&#8217;s Labs Q1 Results FY27 Outlook for the Full Year<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#Dr_Reddys_Labs_Stock_Performance_After_the_Q1_Results\" title=\"Dr Reddy&#8217;s Labs Stock Performance After the Q1 Results\">Dr Reddy&#8217;s Labs Stock Performance After the Q1 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#Key_Risks\" title=\"Key Risks\">Key Risks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#1_Continued_US_Pricing_Pressure\" title=\"1. Continued US Pricing Pressure\">1. Continued US Pricing Pressure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#2_Semaglutide_Launch_Timeline_Uncertainty\" title=\"2. Semaglutide Launch Timeline Uncertainty\">2. Semaglutide Launch Timeline Uncertainty<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#3_Regulatory_and_Manufacturing_Risk\" title=\"3. Regulatory and Manufacturing Risk\">3. Regulatory and Manufacturing Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#Frequently_Asked_Questions_on_Dr_Reddys_Labs_Q1_Results_FY27\" title=\"Frequently Asked Questions on Dr Reddy&#8217;s Labs Q1 Results FY27\">Frequently Asked Questions on Dr Reddy&#8217;s Labs Q1 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#When_were_the_Dr_Reddys_Labs_Q1_results_FY27_announced\" title=\"When were the Dr Reddy&#8217;s Labs Q1 results FY27 announced?\">When were the Dr Reddy&#8217;s Labs Q1 results FY27 announced?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#What_is_the_PAT_in_the_Dr_Reddys_Labs_Q1_results_FY27\" title=\"What is the PAT in the Dr Reddy&#8217;s Labs Q1 results FY27?\">What is the PAT in the Dr Reddy&#8217;s Labs Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#Why_did_Dr_Reddys_profit_fall_so_sharply_in_Q1_FY27\" title=\"Why did Dr Reddy&#8217;s profit fall so sharply in Q1 FY27?\">Why did Dr Reddy&#8217;s profit fall so sharply in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#What_was_the_EBITDA_margin_in_the_Dr_Reddys_Labs_Q1_results_FY27\" title=\"What was the EBITDA margin in the Dr Reddy&#8217;s Labs Q1 results FY27?\">What was the EBITDA margin in the Dr Reddy&#8217;s Labs Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#What_happened_with_Dr_Reddys_semaglutide_product\" title=\"What happened with Dr Reddy&#8217;s semaglutide product?\">What happened with Dr Reddy&#8217;s semaglutide product?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#How_did_the_share_price_react_to_the_Dr_Reddys_Labs_Q1_results_FY27\" title=\"How did the share price react to the Dr Reddy&#8217;s Labs Q1 results FY27?\">How did the share price react to the Dr Reddy&#8217;s Labs Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#Is_the_stock_a_good_buy_after_the_Dr_Reddys_Labs_Q1_results_FY27\" title=\"Is the stock a good buy after the Dr Reddy&#8217;s Labs Q1 results FY27?\">Is the stock a good buy after the Dr Reddy&#8217;s Labs Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-labs-q1-results-fy27-pat-444-crore\/#Where_can_I_verify_the_Dr_Reddys_Labs_Q1_results_FY27\" title=\"Where can I verify the Dr Reddy&#8217;s Labs Q1 results FY27?\">Where can I verify the Dr Reddy&#8217;s Labs Q1 results FY27?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Reddys_Labs_Q1_Results_FY27_Key_Takeaways\"><\/span><strong>Dr Reddy&#8217;s Labs Q1 Results FY27 Key Takeaways<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Here are the most important numbers from the Dr Reddy&#8217;s Labs Q1 results FY27 at a glance.<\/p>\n<ul>\n<li>Net Profit (PAT): Rs 444 Cr in Q1 FY27 versus Rs 1,418 Cr in Q1 FY26, down 68.7% year on year, against a Street estimate of Rs 737 Cr.<\/li>\n<li>Revenue: Rs 8,100 Cr in Q1 FY27 versus Rs 8,572 Cr in Q1 FY26, down 5.5% year on year, against an estimate of Rs 8,221 Cr.<\/li>\n<li>EBITDA: Rs 861 Cr in Q1 FY27 versus Rs 2,173 Cr in Q1 FY26, down 60.4% year on year, against an estimate of Rs 1,398 Cr.<\/li>\n<li>EBITDA margin collapsed to 10.6% from 25.3% a year ago, well below the 17% estimate.<\/li>\n<li>Global Generics revenue, which includes the key US business, fell 4.8% to Rs 7,208 Cr.<\/li>\n<li>Dr Reddy&#8217;s share price fell 1.92% to Rs 1,182.80 on the NSE on the results day.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Reddys_Labs_Q1_Results_FY27_Financial_Highlights\"><\/span><strong>Dr Reddy&#8217;s Labs Q1 Results FY27 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below summarises the consolidated numbers reported in the Dr Reddy&#8217;s Labs Q1 results FY27 against both the year ago quarter and Street estimates.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Q1 FY27 Actual<\/th>\n<th>Q1 FY26<\/th>\n<th>Street Estimate<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue<\/td>\n<td>Rs 8,100 Cr<\/td>\n<td>Rs 8,572 Cr<\/td>\n<td>Rs 8,221 Cr<\/td>\n<\/tr>\n<tr>\n<td>EBITDA<\/td>\n<td>Rs 861 Cr<\/td>\n<td>Rs 2,173 Cr<\/td>\n<td>Rs 1,398 Cr<\/td>\n<\/tr>\n<tr>\n<td>Net Profit (PAT)<\/td>\n<td>Rs 444 Cr<\/td>\n<td>Rs 1,418 Cr<\/td>\n<td>Rs 737 Cr<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All figures are on a consolidated basis as reported for the quarter ended 30 June 2026. Other income rose to Rs 355 crore from Rs 290 crore a year ago, providing some cushion to an otherwise weak quarter.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Reddys_Labs_Q1_Results_FY27_Performance_Analysis\"><\/span><strong>Dr Reddy&#8217;s Labs Q1 Results FY27 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/sebi-registered-investment-advisor-india\"><strong>Get Personalised Guidance from a SEBI-Registered Investment Advisor<\/strong><\/a><\/p>\n<p>A steep margin collapse defines the Dr Reddy&#8217;s Labs Q1 results FY27. The EBITDA margin fell to 10.6% from 25.3% a year ago, nearly halving even against the Street&#8217;s own reduced estimate of 17%, showing analysts had underestimated the scale of the pressure facing the business this quarter.<\/p>\n<p>Brokerages had flagged ahead of the results that profit would likely decline on lower contribution from key products and intense US generics competition. The Global Generics segment, which includes the US business, saw revenue decline 4.8% to Rs 7,208 crore, consistent with this pressure.<\/p>\n<p>Separately, the company disclosed on 9 July 2026 an out-of-specification API issue in certain semaglutide batches, delaying commercial supplies while it investigates, with no stated impact on patient safety or filings. This likely added to the quarter&#8217;s pressure.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Reddys_Labs_Q1_Results_FY27_Key_Business_Factors\"><\/span><strong>Dr Reddy&#8217;s Labs Q1 Results FY27: Key Business Factors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_US_Generics_Pricing_and_Competitive_Pressure\"><\/span><strong>1. US Generics Pricing and Competitive Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Intense competition and pricing erosion in the US generics market, the company&#8217;s largest revenue contributor, is the primary driver cited by analysts behind the sharp margin decline in the Dr Reddy&#8217;s Labs Q1 results FY27.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Semaglutide_Supply_Delay\"><\/span><strong>2. Semaglutide Supply Delay<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The disclosed API quality issue delaying commercial supply of the company&#8217;s semaglutide metabolic therapy product removed an anticipated revenue contributor from the quarter, adding to the topline and margin pressure.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Broad_Based_Miss_Against_Estimates\"><\/span><strong>3. Broad Based Miss Against Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Every key metric, revenue, EBITDA and PAT, missed Street estimates by a wide margin, suggesting the scale of the pressure was underappreciated going into the results.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_Details\"><\/span><strong>Dividend Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Any dividend announcement accompanying the June 2026 quarter results will be reflected in the company&#8217;s official NSE and BSE filings. Investors should rely on those filings for dividend confirmation rather than secondary sources.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Reddys_Labs_Q1_Results_FY27_Outlook_for_the_Full_Year\"><\/span><strong>Dr Reddy&#8217;s Labs Q1 Results FY27 Outlook for the Full Year<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>After the results, the key questions for FY27 are how quickly the semaglutide supply issue resolves, whether US pricing pressure stabilises, and what new launches management can point to as offsets. Given the scale of the miss, the earnings call commentary will be watched closely for margin recovery guidance.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Reddys_Labs_Stock_Performance_After_the_Q1_Results\"><\/span><strong>Dr Reddy&#8217;s Labs Stock Performance After the Q1 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Dr Reddy&#8217;s Laboratories live share price and upcoming quarterly results.<\/em><\/p>\n<p>Dr Reddy&#8217;s share price fell 1.92% to Rs 1,182.80 on the NSE after the Dr Reddy&#8217;s Labs Q1 results FY27, as the market absorbed a sharp miss across every reported line.<\/p>\n<p>Investors can compare the trend of the counter with the broader pharma sector to judge how the stock is placed relative to peers after the Dr Reddy&#8217;s Labs Q1 results FY27.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks\"><\/span><strong>Key Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Investors going through the fine print of the Dr Reddy&#8217;s Labs Q1 results FY27 should also weigh the following risks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"1_Continued_US_Pricing_Pressure\"><\/span><strong>1. Continued US Pricing Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Persistent competitive intensity and pricing erosion in US generics could delay margin recovery beyond current market expectations.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Semaglutide_Launch_Timeline_Uncertainty\"><\/span><strong>2. Semaglutide Launch Timeline Uncertainty<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The resolution timeline for the disclosed API quality issue remains uncertain, and further delays would extend the revenue and margin pressure visible in the Dr Reddy&#8217;s Labs Q1 results FY27.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Regulatory_and_Manufacturing_Risk\"><\/span><strong>3. Regulatory and Manufacturing Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Further US FDA inspection findings or compliance issues at its regulated facilities could add to near term uncertainty.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Dr Reddy&#8217;s Labs Q1 results FY27 show a sharp miss with net profit down 68.7% at Rs 444 crore against a Street estimate of Rs 737 crore, driven by US generics pricing pressure and a disclosed semaglutide supply delay. Investors should track the earnings call commentary for a margin recovery timeline and consult a SEBI-registered advisor before acting on the numbers.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Dr_Reddys_Labs_Q1_Results_FY27\"><\/span><strong>Frequently Asked Questions on Dr Reddy&#8217;s Labs Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_were_the_Dr_Reddys_Labs_Q1_results_FY27_announced\"><\/span><strong>When were the Dr Reddy&#8217;s Labs Q1 results FY27 announced?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Dr Reddy&#8217;s Labs Q1 results FY27 were announced on Wednesday, 22 July 2026, for the quarter ended 30 June 2026, on a consolidated basis.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PAT_in_the_Dr_Reddys_Labs_Q1_results_FY27\"><\/span><strong>What is the PAT in the Dr Reddy&#8217;s Labs Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The consolidated PAT in the Dr Reddy&#8217;s Labs Q1 results FY27 stood at Rs 444 crore, down 68.7% from Rs 1,418 crore in Q1 FY26, and well below the Street estimate of Rs 737 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_Dr_Reddys_profit_fall_so_sharply_in_Q1_FY27\"><\/span><strong>Why did Dr Reddy&#8217;s profit fall so sharply in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Dr Reddy&#8217;s Labs Q1 results FY27 reflect intense competition and pricing pressure in the US generics market, the company&#8217;s largest revenue segment, along with a disclosed delay in commercial supplies of its semaglutide product due to an active pharmaceutical ingredient quality issue found on 9 July 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_EBITDA_margin_in_the_Dr_Reddys_Labs_Q1_results_FY27\"><\/span><strong>What was the EBITDA margin in the Dr Reddy&#8217;s Labs Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The EBITDA margin in the Dr Reddy&#8217;s Labs Q1 results FY27 collapsed to 10.6% from 25.3% a year ago, well below the Street estimate of 17%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_happened_with_Dr_Reddys_semaglutide_product\"><\/span><strong>What happened with Dr Reddy&#8217;s semaglutide product?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The company identified an issue with the active pharmaceutical ingredient used in certain batches of semaglutide, causing it to be out of specification. This is delaying commercial supplies of the metabolic therapy while the company investigates, though it stated there is no impact on patient safety or existing regulatory filings.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_the_share_price_react_to_the_Dr_Reddys_Labs_Q1_results_FY27\"><\/span><strong>How did the share price react to the Dr Reddy&#8217;s Labs Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Reddy&#8217;s Laboratories share price fell 1.92% to Rs 1,182.80 on the NSE after the Dr Reddy&#8217;s Labs Q1 results FY27.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_the_stock_a_good_buy_after_the_Dr_Reddys_Labs_Q1_results_FY27\"><\/span><strong>Is the stock a good buy after the Dr Reddy&#8217;s Labs Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Dr Reddy&#8217;s Labs Q1 results FY27 show a sharp miss driven by US pricing pressure and a product supply delay, both factors investors should track for signs of resolution. This article is for educational purposes only. Consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_verify_the_Dr_Reddys_Labs_Q1_results_FY27\"><\/span><strong>Where can I verify the Dr Reddy&#8217;s Labs Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The official filings for the June 2026 quarter are available on the NSE and BSE websites, and the stock can be tracked on the Univest app.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"When were the Dr Reddy's Labs Q1 results FY27 announced?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Dr Reddy's Labs Q1 results FY27 were announced on Wednesday, 22 July 2026, for the quarter ended 30 June 2026, on a consolidated basis.\"}},{\"@type\":\"Question\",\"name\":\"What is the PAT in the Dr Reddy's Labs Q1 results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The consolidated PAT in the Dr Reddy's Labs Q1 results FY27 stood at Rs 444 crore, down 68.7% from Rs 1,418 crore in Q1 FY26, and well below the Street estimate of Rs 737 crore.\"}},{\"@type\":\"Question\",\"name\":\"Why did Dr Reddy's profit fall so sharply in Q1 FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Dr Reddy's Labs Q1 results FY27 reflect intense competition and pricing pressure in the US generics market, the company's largest revenue segment, along with a disclosed delay in commercial supplies of its semaglutide product due to an active pharmaceutical ingredient quality issue found on 9 July 2026.\"}},{\"@type\":\"Question\",\"name\":\"What was the EBITDA margin in the Dr Reddy's Labs Q1 results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The EBITDA margin in the Dr Reddy's Labs Q1 results FY27 collapsed to 10.6% from 25.3% a year ago, well below the Street estimate of 17%.\"}},{\"@type\":\"Question\",\"name\":\"What happened with Dr Reddy's semaglutide product?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The company identified an issue with the active pharmaceutical ingredient used in certain batches of semaglutide, causing it to be out of specification. This is delaying commercial supplies of the metabolic therapy while the company investigates, though it stated there is no impact on patient safety or existing regulatory filings.\"}},{\"@type\":\"Question\",\"name\":\"How did the share price react to the Dr Reddy's Labs Q1 results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr Reddy's Laboratories share price fell 1.92% to Rs 1,182.80 on the NSE after the Dr Reddy's Labs Q1 results FY27.\"}},{\"@type\":\"Question\",\"name\":\"Is the stock a good buy after the Dr Reddy's Labs Q1 results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Dr Reddy's Labs Q1 results FY27 show a sharp miss driven by US pricing pressure and a product supply delay, both factors investors should track for signs of resolution. This article is for educational purposes only. Consult a SEBI-registered advisor before investing.\"}},{\"@type\":\"Question\",\"name\":\"Where can I verify the Dr Reddy's Labs Q1 results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The official filings for the June 2026 quarter are available on the NSE and BSE websites, and the stock can be tracked on the Univest app.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr Reddy&#8217;s Labs Q1 results FY27: net profit plunges 68.7% to Rs 444 crore, missing estimates sharply, as US pricing pressure and a semaglutide supply delay hit the quarter. Stock down 1.92% at Rs 1,182.80.<\/p>\n","protected":false},"author":35,"featured_media":165187,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[4796],"class_list":["post-165161","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-q1-results-fy27"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1784721391:29"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["44"],"rank_math_title":["Dr Reddy's Q1 Results FY27: PAT Falls 68.7%, Misses Estimates"],"rank_math_description":["Dr Reddy's Labs Q1 results FY27: PAT plunges 68.7% to Rs 444 Cr, missing the Rs 737 Cr estimate on US pricing pressure and a supply delay. Full highlights here."],"rank_math_focus_keyword":["Dr Reddy's Labs Q1 results FY27"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["165187"],"_edit_last":["29"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["29511"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/07\/Dr-Reddys-Labs-Q1-Results-FY27.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/165161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=165161"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/165161\/revisions"}],"predecessor-version":[{"id":165191,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/165161\/revisions\/165191"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/165187"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=165161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=165161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=165161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}